An observational study in Acute Myeloid Leukemia (AML) and MLL Rearrangement, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 6 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Peking University People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital — 15 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · Peking University People's Hospital.
Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, this one is one of 2 that started in 2025, is one of 3 observational ones, reaches primary completion later than 4 of the 15 other live ones, and was the 18th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →15 of the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 18–70
Peking University People's Hospital · Sites in China
Ages 18–70
Peking University People's Hospital · Sites in China
Peking University People's Hospital · Sites in China
Ages 55–70
Peking University People's Hospital · Sites in China
Ages up to 18
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 6 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2013; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is above the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 52 across the 17 interventional studies, 210 across the 3 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.
5 of the studies in Leukemia, Myeloid, Acute by Peking University People's Hospital that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06802718Phase 3Peking University People's HospitalInterferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | 2026-12 |
| NCT07449286Peking University People's HospitalIFN-α in Relapse Prevention. | 2026-12-31 |
| NCT07319793Peking University People's HospitalPre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT | 2027-01-01 |
| NCT06301425Peking University People's HospitalMRD Response-adapted Allo-HSCT for Adverse-risk AML | 2027-05-01 |
| NCT07925554Peking University People's HospitalInterferon-α Maintenance in Favorable-Risk AML | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:
Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation.
Exclusion Criteria:
AML patients with MLL rearrangement who recieved chemnoptherapy or unerwent allo-SCT
Diagnostic Test: Detection of leukemia stem cell using multiparameter flow cytometry
For AML patients with MLL rearrangement enrolled, leukemia stem cell will be detcted at diagnosis and during follow-up. A traditional Minimal residual disease was deteced as normal medical care, simultaneously, leukemia stem cell will be detcted using the sample bone marrow sample.
Relapse
Relapse was defined by the morphological evidence of disease in the peripheral blood, BM or extramedullary sites
Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.
leukemia-free survival
Leukemia-free survival was defined as survival in continuous complete remission.
Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.
overall survival
Overall survival referred to patients who survived until the final follow-up time point
Time frame: Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.
Plan to share: Undecided
Started Jun 2025 (actual). Primary completion is estimated for Apr 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital →